Interference with clinical laboratory analyses.

M H Kroll; R J Elin

Home/Archive/PubMed

PubMed · 7955368

Interference with clinical laboratory analyses.

M H Kroll·R J Elin

View original source ↗Export metadata ↓

Abstract

Interference by endogenous and exogenous substances with assays for clinical analytes is a common problem in laboratory medicine. For this review, we defined interference as "the effect of a substance present in the sample that alters the correct value of the result, usually expressed as concentration or activity, for an analyte." There are four major endogenous compounds that consistently interfere with laboratory results: hemoglobin, bilirubin, lipids, and paraproteins. The major exogenous sources of interference are drugs prescribed for the patient; and there are several excellent compendia of the effect of drugs on clinical laboratory tests. We recommend determining whether the interference is dependent or independent of the analyte for the assay. Further, we propose an approach to the identification and resolution of an interference problem for the clinical laboratory and make recommendations to manufacturers.

Explore related subjects

Bilirubin Chemistry, Clinical Clinical Laboratory Information Systems Hemoglobins Humans Laboratories Lipids Paraproteinemias Pharmaceutical Preparations Quality Control Sensitivity and Specificity Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

M H Kroll, R J Elin. 1994. Interference with clinical laboratory analyses.. https://pubmed.ncbi.nlm.nih.gov/7955368/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Structure of pressure-induced denatured state of human serum albumin: a comparison with the intermediate in urea-induced denaturation.

The structure of human serum albumin (HSA) in the pressure-induced denatured state was investigated by fluorescence spectroscopy. HSA undergoes a conformational change in the pressure range from 0.1 MPa to 400 MPa, at 25 degrees C. Several ligands bind to specific sites in HSA, and the fluorescence spectra of these ligands were used to study the conformational state of this protein. The warfarin-binding site (site I) and the dansylsarcosine-binding site (site II), are located in subdomains II and III, respectively. The fluorescence spectra of these probes reflected the structural changes in each of these subdomains. Dansylsarcosine completely dissociated from its binding site in domain III above 300 MPa, but substantial affinity of warfarin remained in this pressure range. Similar results were obtained for the urea-induced denaturation of HSA; although dansylsarcosine completely dissociated at urea concentration above 6 M, warfarin remained bound to site I in domain II at these concentrations. These results suggest that the structure of domain III is unfolded both in the initial stages of both pressure- and urea-induced denaturation of HSA. HSA possesses a single tryptophan residue (Trp-214) in domain II, and fluorescence from this residue reflects structural changes in this domain. In the urea-induced denatured state of HSA, a red-shift in the wavelength of maximum fluorescence occurred over urea concentrations ranging from 4 M to 6 M. This shift indicated that a structural change in domain II occurred simultaneously with the unfolding of domain III in this concentration range. On other hand, the shift in the wavelength of maximum fluorescence of Trp-214 was comparatively small in the pressure range from 0.1 MPa to 400 MPa indicating that the environment of Trp-214 was not affected. These results indicate that preferential unfolding of domain III occurs in the pressure-induced denatured state of HSA.

Bilirubin↗

PubMed1997

Increased expression of low-density lipoprotein receptors in a Smith-Lemli-Opitz infant with elevated bilirubin levels.

We report on an infant girl with severe RSH or Smith-Lemli-Opitz syndrome with hyperbilirubinemia. The infant died at age 2 months. Sterol analysis of liver and brain tissues showed marked elevations of 7-dehydrocholesterol with decreased levels of cholesterol. Immunocytochemical analysis demonstrated remarkable increases in low-density lipoprotein (LDL) receptors in these tissues, indicative of a deficiency in available cholesterol for tissue needs.

Bilirubin↗

PubMed1997

[Hyperbilirubinemia in healthy full-term neonates: guidelines for diagnosis and treatment. Ad-hoc Commission Hyperbilirubinemia and Phototherapy of the Section Neonatology of the Netherlands Society for Pediatrics].

In healthy full-term neonates without haemolytic disease, hyperbilirubinaemia is not associated with neurological, auditory or cognitive disorders later in life. Therefore, the new threshold levels of hyperbilirubinaemia at which further diagnosis and treatment are indicated, are higher than the former ones.

Bilirubin↗